These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 23550846

  • 1. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS.
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW, Lo M, Crank CW.
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [Abstract] [Full Text] [Related]

  • 3. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.
    Cairo MS, Thompson S, Tangirala K, Eaddy MT.
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):173-178. PubMed ID: 27965022
    [Abstract] [Full Text] [Related]

  • 4. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Laadem A, Seiter K.
    J Clin Oncol; 2010 Sep 20; 28(27):4207-13. PubMed ID: 20713865
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
    McBride A, Lathon SC, Boehmer L, Augustin KM, Butler SK, Westervelt P.
    Pharmacotherapy; 2013 Mar 20; 33(3):295-303. PubMed ID: 23456733
    [Abstract] [Full Text] [Related]

  • 8. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
    Campara M, Shord SS, Haaf CM.
    J Clin Pharm Ther; 2009 Apr 20; 34(2):207-13. PubMed ID: 19250141
    [Abstract] [Full Text] [Related]

  • 9. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
    Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, Pieters R, Uyttebroeck A.
    Support Care Cancer; 2003 Apr 20; 11(4):249-57. PubMed ID: 12673464
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK, Chiang AK, Chan GC, Ha SY.
    Cochrane Database Syst Rev; 2014 Aug 14; (8):CD006945. PubMed ID: 25121561
    [Abstract] [Full Text] [Related]

  • 13. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H.
    Cancer; 2003 Sep 01; 98(5):1048-54. PubMed ID: 12942574
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of single-dose rasburicase in an obese female.
    Arnold TM, Reuter JP, Delman BS, Shanholtz CB.
    Ann Pharmacother; 2004 Sep 01; 38(9):1428-31. PubMed ID: 15292497
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK, Chiang AK, Chan GC, Ha SY.
    Cochrane Database Syst Rev; 2017 Mar 08; 3(3):CD006945. PubMed ID: 28272834
    [Abstract] [Full Text] [Related]

  • 18. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A.
    Am J Kidney Dis; 2013 Sep 08; 62(3):481-92. PubMed ID: 23684124
    [Abstract] [Full Text] [Related]

  • 19. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA, Herrera N, Rohatgi R.
    Pediatr Blood Cancer; 2018 Oct 08; 65(10):e27236. PubMed ID: 29905398
    [Abstract] [Full Text] [Related]

  • 20. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.
    Yu X, Liu L, Nie X, Li J, Zhang J, Zhao L, Wang X.
    J Clin Pharm Ther; 2017 Feb 08; 42(1):18-26. PubMed ID: 27888526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.